Allopathy
Prescription Required
DCGI (Drugs Controller General of India)
Schedule H
Encainide is an antiarrhythmic Class l c agent belonging to a Sodium channel blocker.
Encainide is used for the management of atrial or ventricular fibrillation, atrial flutter, and ventricular tachycardia.
Encainide is a sodium channel blocker, binding to voltage-gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.
The onset of Action of Encainide was within 3 hours.
The Tmax was about 1.8 - 2 hr and Cmax was about nine h, respectively
Encainide is available in the form of a dosage form such as capsules.
Encainide is used for the management of atrial or ventricular fibrillation, atrial flutter, and ventricular tachycardia.
Encainide is a sodium channel blocker, binding to voltage-gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.
Encainide is used for the management of atrial or ventricular fibrillation, atrial flutter, and ventricular tachycardia.
The dosage and the duration of treatment should be as per the clinical judgment of the treating physician
Encainide is available in various dosage strengths: 25 mg and 35 mg.
Encainide is available in the form of a dosage form such as capsules.
Encainide may be contraindicated in the following
- Allergy to class/drug
- Preexisting 2nd or 3rd-degree AV block
- Preexisting right bundle branch block w/ left hemiblock
- Presence of cardiogenic shock
The adverse reactions related to molecule Encainide can be categorized as
- Common Adverse effects:
Provocation or aggravation of ventricular arrhythmias, 2nd or 3rd-degree AV block, Sinus bradycardia
- Less Common adverse effects:
Dizziness, Blurred/abnormal vision, Headache
- Rare adverse effects:
Bradycardia, decompensated heart failure, cardiac arrest, and heart block.
The clinically relevant drug interactions of Encainide are briefly summarized here.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatric Use
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Pharmacodynamics:
Used to treat irregular heartbeats, encainide decreases excitability, conduction velocity, and automaticity as a result of slowed atrial, atrioventricular (AV) nodal, His-Purkinje, and intraventricular conduction. It causes a slight but significant prolongation of refractory periods in these tissues. The greatest effect is on the His-Purkinje system. Encainide decreases the rate of rising of the action potential without markedly affecting its duration.
Pharmacokinetics:
Metabolism: Hepatic; Encainide converts to two active metabolites.
Excretion: Urine and feces
- https://www.clinicaltrials.gov/ct2/show/NCT00236249
- https://www.clinicaltrials.gov/ct2/show/NCT02852434
- https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C48000
1.https://wikem.org/wiki/Encainide
2. https://www.rxwiki.com/encainide
3.https://www.apollopharmacy.in/salt/ENCAINIDE
